Cenduit came to life in May 2007 as a result of a joint venture between the two leading clinical development and clinical supply chain organizations: Quintiles and Thermo Fisher Scientific. Both parent companies recognized the rapidly increasing demand for patient randomization and drug supply management services and seized the opportunity through the creation of a specialized IRT (IVR/IWR) solutions provider.
Backed by Quintiles’ unparalleled clinical development experience and using Thermo Fisher Scientific’s unmatched clinical supply chain know-how, Cenduit was able to hit the ground running with a powerful solution that enabled sponsor companies to gain control of the drug development process.
Hundreds of IRT-driven trials later, Cenduit has established itself as a leader in the field with a proven track record of smoother studies and happier investigator sites. Cenduit’s Quality First culture and its unrivaled ability to design supply chain processes and build a customized IRT system to meet its sponsors’ study-specific requirements continues to elevate the company’s reputation.
Cenduit was created by two industry leaders in response to the growing demand for customized patient randomization and drug supply management solutions, and stands strong as the only IRT specialist in the world. With continued support from its parent companies, Cenduit will enable seamless patient randomization and treatment allocation to patients around the globe, on time, every time.